Evidence map›Paper›PMID 29656586›Full record

Trial reportCancer medicine2018

Prospective assessment of the predictive value of the BRCA1 gene status in sarcoma patients treated with trabectedin: an updated analysis of the EORTC 62091 trial.

Antoine Italiano, Nathan Touati, Saskia Litière, Françoise Collin, Philippe Pourquier, Alessandro Gronchi

Open access · goldAbstract readClinical Trial, Phase IIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Cancer medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 8 citations in OpenAlex.

  1. Trial
  2. Review
  3. The Role of Trabectedin in Soft Tissue Sarcoma.Frontiers in pharmacology · 2022
    Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 4 countries.

Antoine ItalianoInstitut Bergonié, Bordeaux, France.ORCID 0000-0002-8540-5351
Nathan TouatiEuropean Organization for Research and Treatment of Cancer, Brussels, Belgium.
Saskia LitièreEuropean Organization for Research and Treatment of Cancer, Brussels, Belgium.
Françoise CollinCentre Georges-François Leclerc, Dijon, France.
Philippe PourquierInstitute of Cancer Research of Montpellier, Montpellier, France.
Alessandro GronchiInstitute of Cancer Research of Montpellier, Montpellier, France.
European Organisation for Research and Treatment of Cancer · BECEA Valduc · FRCentre Georges François Leclerc · FRInserm · FRInstitut de Recherche en Cancérologie de Montpellier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We describe the predictive value of BRCA1 gene status on trabectedin efficacy and found no correlation despite the mechanisms of action of this drug that rely on DNA repair systems.

Indexed as

Antineoplastic Agents, AlkylatingBRCA1 ProteinSarcomaTrabectedinFemaleGenotypeHumansMalePredictive Value of TestsProspective StudiesTreatment OutcomeAntineoplastic Agents, AlkylatingBRCA1 ProteinBRCA1 protein, humanTrabectedin

Identifiers

PMID29656586
PMCPMC5943428
OpenAlexW2801926848

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.